ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS announced the completion of the final report for the Good Laboratory Practice (GLP) safety study in non-human primates of the ES2B-C001 (HER2-VLP) breast cancer vaccine candidate. This significant milestone marks an important step towards enabling a clinical trial application. The Company is currently focusing on Good Manufacturing Practice (GMP) production and designing the Phase I clinical trial, with the aim to initiate the Phase I trial within the next year.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.306 SEK | +1.24% | -1.66% | -38.10% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-38.10% | 6.22M | |
-2.91% | 89.01B | |
-4.34% | 37.79B | |
-17.08% | 31.22B | |
+59.95% | 26.1B | |
-22.15% | 14.25B | |
-9.36% | 12.8B | |
-11.39% | 11.65B | |
-46.06% | 10.88B | |
+3.45% | 8.7B |
- Stock Market
- Equities
- EXPRS2 Stock
- News ExpreS2ion Biotech Holding AB
- ExpreS2ion Announces Completion of GLP Safety Study for ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate